# DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER

> **NCT07690540** · NA · RECRUITING · sponsor: **European Institute of Oncology** · enrollment: 510 (estimated)

## Conditions studied

- Endometrial Cancer
- Immune Checkpoint Inhibitors

## Interventions

- **BIOLOGICAL:** Prospective exploratory cohort

## Key facts

- **NCT ID:** NCT07690540
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-14
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2026-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07690540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07690540, "DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07690540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*